Clinical Trials Logo

Generalized Lipodystrophy clinical trials

View clinical trials related to Generalized Lipodystrophy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04159415 Active, not recruiting - Clinical trials for Generalized Lipodystrophy

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

Start date: January 7, 2020
Phase: Phase 2
Study type: Interventional

The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on fasting triglyceride levels in the subset of patients with elevated baseline fasting triglycerides (TG ≥250 mg/dL). The secondary objectives are to estimate the effects of REGN4461 on a composite endpoint of changes in either HbA1c or fasting TG for all patients, estimate the effects of 3 dose levels of REGN4461 on glycemic parameters and fasting TG, to estimate the effects of REGN4461 on insulin sensitivity, to evaluate the safety and tolerability of REGN4461 and to evaluate the pharmacokinetics (PK) and immunogenicity of REGN4461.

NCT ID: NCT04026178 Active, not recruiting - Clinical trials for Generalized Lipodystrophy

Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

Start date: November 14, 2018
Phase: Phase 4
Study type: Interventional

MYALEPT™ (metreleptin) has been approved as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (MYALEPT Prescribing Information). This study is a multicenter, open-label, Phase 4 trial to provide an assessment of the immunogenicity associated with metreleptin and of any major potential risks due to development of antibodies to metreleptin. The study is being conducted to comply with a postmarketing requirement.